Equities researchers at BTIG Research initiated coverage on shares of Cullinan Oncology (NASDAQ:CGEM – Get Rating) in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm set a “buy” rating on the stock.
Cullinan Oncology Stock Performance
NASDAQ CGEM opened at $12.76 on Monday. The firm’s 50 day moving average price is $12.57 and its two-hundred day moving average price is $12.70. The stock has a market cap of $581.98 million, a price-to-earnings ratio of 5.75 and a beta of -0.09. Cullinan Oncology has a twelve month low of $7.30 and a twelve month high of $20.01.
Cullinan Oncology (NASDAQ:CGEM – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.43. On average, research analysts forecast that Cullinan Oncology will post -3.67 EPS for the current fiscal year.
Insider Transactions at Cullinan Oncology
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of CGEM. Amalgamated Bank bought a new stake in shares of Cullinan Oncology in the 1st quarter valued at approximately $34,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Cullinan Oncology in the third quarter worth approximately $48,000. Barclays PLC increased its stake in shares of Cullinan Oncology by 23.8% during the 3rd quarter. Barclays PLC now owns 8,994 shares of the company’s stock worth $116,000 after purchasing an additional 1,731 shares during the last quarter. Annandale Capital LLC bought a new position in shares of Cullinan Oncology during the 3rd quarter valued at $128,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Cullinan Oncology in the 3rd quarter valued at $145,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
About Cullinan Oncology
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- NVIDIA Corporation: Too Many Comeback Catalysts to Ignore
- Is This The Right Time to Invest in Alibaba?
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.